Brought to you by 
Cubist, Teva settle litigation surrounding Cubicin
23 May 2012
Executive Summary
Cubist Pharmaceuticals Inc. (therapies for the acute care market) and Teva Pharmaceutical Industries Ltd. have settled patent litigation surrounding the former’s antibiotic Cubicin (daptomycin). In early 2009, Cubist claimed Teva infringed on patents by filing for FDA approval of a generic version of the drug. Under terms of the settlement, Cubist licensed Teva non-exclusive rights to sell daptomycin in the US as of either December 24, 2017 or, if Cubist obtains a six-month extension of pediatric marketing exclusivity, then June 24, 2018. Teva will exclusively purchase its daptomycin requirements from Cubist based on both the cost of goods sold plus a margin and a specified percentage of net profits from sales of generic daptomycin.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cubist, Teva settle litigation surrounding Cubicin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice